STOCK TITAN

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
TScan Therapeutics, Inc. (TCRX) will participate in the Cell Therapy Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference. The event will be held on March 6, 2024, at 9:10 a.m. Eastern Time in Boston. A webcast of the panel discussion will be available on the company's website.
Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in the Cell Therapy Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference being held at the Marriott Copley Place in Boston on Wednesday, March 6, 2024 at 9:10 a.m. Eastern Time.

A webcast of the panel discussion will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized, enhanced, multiplexed TCR-T therapies for patients with a variety of cancers.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com


TScan Therapeutics, Inc. (TCRX) will participate in the Cell Therapy Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference on March 6, 2024, at 9:10 a.m. Eastern Time.

The event will be held at the Marriott Copley Place in Boston.

A webcast of the panel discussion will be available on the 'Events and Presentations' section of the Company’s website at ir.tscan.com.

An archived replay of the webcast will be available on the Company’s website for 30 days following the event.
Tscan Therapeutics Inc

NASDAQ:TCRX

TCRX Rankings

TCRX Latest News

TCRX Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link

About TCRX

harnessing novel t cell systems to extend the promise of immunotherapy